Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aHVEM17
- Development stage
- Preclinical
- Lead developer
- City of Hope
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
aHVEM17 is a fully humanized monoclonal antibody targeting herpesvirus entry mediator (HVEM, also known as TNFRSF14). Developed by City of Hope National Medical Center in collaboration with TGEN, it is being investigated for the treatment of multiple myeloma. aHVEM17 binds to HVEM with high affinity and exerts potent anti-tumor activity by inducing natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Additionally, it blocks the interaction between HVEM and B- and T-lymphocyte attenuator (BTLA), functioning as an immune checkpoint inhibitor.
02
Targets
TNFRSF14 (Tumor necrosis factor receptor superfamily member 14)
Beyond the preview
Go deeper on aHVEM17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aHVEM17.